Japanese drug maker Daiichi Sankyo, the majority shareholder in Indian pharma major Ranbaxy Laboratories, plans to raise 100 billion yen (about $1.04 billion) through public issue of bonds.
Daiichi would be issuing bonds worth 60 billion yen and 40 billion yen, respectively, it said in a statement today.
The company would be issuing bonds in two tranches, with maturity period of five years and 10 years, respectively. The bond offering began today.
The first series of bonds worth 60 billion yen would have a maturity period of five years. The remaining bonds of 40 billion yen would have a maturity period of 10 years.
Daiichi said the denomination of each bond in the offering would be 100 million yen.
The Japanese entity which has a controlling stake in Ranbaxy, recently said its full-year losses narrowed to 215.59 billion yen (about $2.2 billion) on account of changes related to accounting guidelines in Japan.
Daiichi has revised its losses to 215.59 billion yen for the year ended 31 March 2009. Earlier, the company had reported a full-year loss of 335.8 billion yen.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
